Home » Teva Gets Approval for Glyburide/Metformin HCl Tablets
Teva Gets Approval for Glyburide/Metformin HCl Tablets
Teva Pharmaceutical has been granted final approval from the FDA for the its abbreviated new drug application for Glyburide and Metformin HCl tablets, 1.25 mg/250 mg, 2.5 mg/500 mg and 5 mg/500 mg.
Shipment of this product is expected to begin shortly.
Teva's Glyburide and Metformin HCl tablets are the AB-rated generic equivalent of Bristol-Myers Squibb's Glucovance tablets, a product indicated as an adjunct to diet and exercise in the treatment of Type 2 diabetes.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct